Business
Teva Stock Soars 19% as Game-Changing IBD Drug Duvakitug Crushes Trial Expectations - Yahoo Finance
Teva up 19%, Sanofi 4% after duvakitug's trial success stuns investors. and for good reason
By: Yahoo Entertainment
- Dec 18 2024
- 0
- 0 Views
Teva Pharmaceutical (NYSE:TEVA) Industries and Sanofi (NASDAQ:SNY) just dropped a game-changing update for investorstheir star drug duvakitug smashed expectations in Phase 2b trials, delivering clini… [+1711 chars]